Navigation Links
CYNACON / OCuSOFT(R) Announces OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies
Date:5/28/2008

eyelids.

OCuSOFT(R), Inc. is dedicated to addressing clinical needs with novel technological solutions that optimize the delivery and performance of ophthalmic pharmaceutical products, which in turn improve patient care and compliance.

For a free sample of OCuSOFT(R) Lid Scrub(TM) PLUS, click: http://www.ocusoft.com/sample1.html.

For more information about the company and their products, visit: http://www.ocusoft.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE OCuSOFT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. CYNACON/OCuSOFT (OCuSOFT, Inc.) Names Katherine M. Mastrota, M.S., O.D. to Medical Scientific Advisory Board
2. Innolife Pharma Inc. Announces The Launching Of A New And Improved Website
3. Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
4. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Express Scripts Inc.
5. Animal Dermatology Clinic Tustin Announces Dr. Russell Muses Appointment as the Member-At-Large for the Executive Board of the American College of Veterinary Dermatology
6. Crimson Announces Acquisition by The Advisory Board Company
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
8. Does Your Child Have Health Insurance? Urban League of Philadelphia Announces Free Open Houses for CHIP Enrollment
9. NxStage Announces $43 Million Private Placement of Equity Securities
10. Nu Skin Enterprises Announces Slate of Candidates for its Board of Directors
11. Pharmacy Technician Certification Board (PTCB) Announces Milestone: 300,000 Certified Pharmacy Technicians (CPhT)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14 2009 56735 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 2Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 3MDS Reports Third Quarter 2009 Financial Results 56733 1MDS Reports Third Quarter 2009 Financial Results 56733 2MDS Reports Third Quarter 2009 Financial Results 56733 3MDS Reports Third Quarter 2009 Financial Results 56733 4MDS Reports Third Quarter 2009 Financial Results 56733 5MDS Reports Third Quarter 2009 Financial Results 56733 6MDS Reports Third Quarter 2009 Financial Results 56733 7MDS Reports Third Quarter 2009 Financial Results 56733 8MDS Reports Third Quarter 2009 Financial Results 56733 9MDS Reports Third Quarter 2009 Financial Results 56733 10MDS Reports Third Quarter 2009 Financial Results 56733 11MDS Reports Third Quarter 2009 Financial Results 56733 12MDS Reports Third Quarter 2009 Financial Results 56733 13MDS Reports Third Quarter 2009 Financial Results 56733 14MDS Reports Third Quarter 2009 Financial Results 56733 15MDS Reports Third Quarter 2009 Financial Results 56733 16MDS Reports Third Quarter 2009 Financial Results 56733 17MDS Reports Third Quarter 2009 Financial Results 56733 18MDS Reports Third Quarter 2009 Financial Results 56733 19MDS Reports Third Quarter 2009 Financial Results 56733 20MDS Reports Third Quarter 2009 Financial Results 56733 21MDS Reports Third Quarter 2009 Financial Results 56733 22MDS Reports Third Quarter 2009 Financial Results 56733 23
Other Medicine Technology:NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8